Novo Nordisk A/S
- Country
- 🇩🇰Denmark
- Ownership
- Public
- Established
- 1923-01-01
- Employees
- 63.3K
- Market Cap
- $602.2B
- Website
- http://www.novonordisk.com
A Study to Understand the Distribution of Obesity Classes and Obesity Related Diseases in People With Obesity Across Countries in Czech Republic, Hungary and Poland
- Conditions
- Obesity
- Interventions
- Other: No treatment given
- First Posted Date
- 2023-04-03
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 1241
- Registration Number
- NCT05795166
- Locations
- 🇭🇺
Dr. Dozsa Katalin Maria EV, Biatorbágy, Hungary
🇵🇱ALLMEDICA sp. z o. o., Nowy Targ, Poland
🇵🇱Clinmedica Research spzo.o, Skierniewice, Poland
A Study to Test How New Long-acting Insulin (Insulin Icodec) Works in the Body of Children and Teenagers
- First Posted Date
- 2023-03-30
- Last Posted Date
- 2025-04-17
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 18
- Registration Number
- NCT05790681
- Locations
- 🇺🇸
Children's Hospital Los Angeles - Endocrinology, Los Angeles, California, United States
🇺🇸Yale New Haven Hospital, Hospital Research Unit, New Haven, Connecticut, United States
🇺🇸Nemours Children's Health, Jacksonville, Florida, United States
A Research Study to Compare How Much Semaglutide is Found in the Blood With Different Tablets of Oral Semaglutide in Healthy Participants
- First Posted Date
- 2023-03-24
- Last Posted Date
- 2024-05-01
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 264
- Registration Number
- NCT05784402
- Locations
- 🇨🇦
Altasciences Clinical Company, Inc, Montreal, Quebec, Canada
🇺🇸Altasciences Clinical LA, Inc., Cypress, California, United States
An Observational Study of Patients With Moderate Parkinson's Disease
- Conditions
- Parkinson Disease
- Interventions
- Other: No treatment given
- First Posted Date
- 2023-03-22
- Last Posted Date
- 2025-04-10
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 96
- Registration Number
- NCT05779475
- Locations
- 🇺🇸
Joe C.Wen & Fam CTR for Adv Care, Irvine, California, United States
🇺🇸NYU Langone Health, New York, New York, United States
🇺🇸NY Presbyt Hosp-W Cornell Med, New York, New York, United States
A Research Study Comparing Blood Levels of Medicines NNC0194-0499 and Semaglutide Administered as a Combination Formulation Versus Two Separate Formulations
- Conditions
- Non-alcoholic Steatohepatitis
- Interventions
- Drug: NNC0194-0499/Semaglutide A (40/0.33mg/mL)Drug: NNC0194-0499/Semaglutide A (40/3.20 mg/mL)
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2024-02-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 53
- Registration Number
- NCT05766709
- Locations
- 🇨🇦
Altasciences Company Inc., Montreal, Quebec, Canada
Barriers to MASLD Management in Europe: Findings From a Multidisciplinary HCP-survey
- Conditions
- Non-alcoholic Steatohepatitis (MASH)Non-alcoholic Fatty Liver Disease (MASLD)
- Interventions
- Other: No treatment given
- First Posted Date
- 2023-03-13
- Last Posted Date
- 2023-10-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 675
- Registration Number
- NCT05765890
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Bangalore, India
DOORS: A Research Study to Understand How Oral Semaglutide Works in People With Type 2 Diabetes Who Change From Dipeptidyl Peptidase-4 Inhibitor (DPP4i) Treatment to Oral Semaglutide in Italy
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2024-05-29
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 390
- Registration Number
- NCT05755360
- Locations
- 🇮🇹
A.O.U. Policlinico S.Orsola, Bologna, Italy
🇮🇹A.O.U. Maggiore della Carità, Piemonte, Italy
🇮🇹P.O. Praia a Mare, Praia a Mare, Italy
A Multinational Survey-based Study to Understand the Real-world Awareness and Perceptions of Systemic inFLAMmation and rolE of hsCRP as a Biomarker in Patients With AtheroSclerotic CardioVascular Disease and Chronic Kidney Disease Among Cardiologists
- Conditions
- Atherosclerotic Cardiovascular Disease (ASCVD)Chronic Kidney Disease (CKD)
- Interventions
- Other: No treatment given
- First Posted Date
- 2023-03-06
- Last Posted Date
- 2023-06-09
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 602
- Registration Number
- NCT05755373
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Bangalore, India
A Research Study Looking at How a Single Dose of the Medicine NNC0194-0499 Behaves in Chinese Men
- Conditions
- Non-alcoholic Fatty Liver Disease
- Interventions
- Drug: NC0194-0499
- First Posted Date
- 2023-02-24
- Last Posted Date
- 2024-06-11
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 24
- Registration Number
- NCT05742919
- Locations
- 🇨🇳
Jinan Central Hospital, Jinan, Shandong, China
Persons With Obesity (PwO) Exploratory Research
- Conditions
- Obesity
- Interventions
- Other: No treatment given
- First Posted Date
- 2023-02-21
- Last Posted Date
- 2023-05-12
- Lead Sponsor
- Novo Nordisk A/S
- Target Recruit Count
- 46
- Registration Number
- NCT05736120
- Locations
- 🇮🇳
Novo Nordisk Investigational Site, Bengaluru, India